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STUDY PROTOCOL Open Access
Improving bereavement outcomes in
Zimbabwe: protocol for a feasibility cluster
trial of the 9-cell bereavement tool
Barbara Mutedzi1* , Lisa Langhaug2, Jennifer Hunt2, Kennedy Nkhoma3 and Richard Harding3
Abstract
Background: The high burden of bereavement in sub-Saharan Africa is largely attributable to HIV, cancer, and
other non-communicable diseases. However, interventions to improve grief and bereavement are rare. Given high
rates of mortality in the context of weak health systems, community lay members are well placed to provide peer
bereavement support. The 9-cell bereavement tool was developed in Zimbabwe to improve community members’
capacity to support the bereaved. This study aims to determine the feasibility of implementing the 9-cell
bereavement tool and recruitment to experimental evaluation.
Methods/design: This feasibility cluster randomized trial with embedded qualitative interviews will be conducted in
two comparable neighborhoods in Zimbabwe. Community leaders from each neighborhood will identify 25 potential
community lay bereavement supporters, each of whom will recruit 2–3 bereaved community members into the trial.
The intervention will be randomly allocated to one community, and the second community will form a wait-list control
(n≥ 75 in each community cluster). Recruitment is estimated to take place over 3 weeks. Measures at T0 (baseline, i.e.,
week 0), T1 (midline, i.e., week 14 or 3 months post-baseline) and T2 (endline, i.e., week 27 or 3 months post-midline)
will address mental health, social support, and levels of grief per individual. Qualitative data will describe lay supporters’
views of intervention training and delivery, and participants’ experience of bereavement support.
Discussion: This is the first documented trial evaluating a bereavement intervention in sub-Saharan Africa. Recruitment,
retention, and measurement data will determine the feasibility of a full trial.
Trial registration: ISRCTN, ISRCTN16484746. Registered 6 February 2018
Keywords: Bereavement, Grief, Bereavement tool, Feasibility cluster trial, Zimbabwe, Africa
Background
Bereavement is the process during which grief is experi-
enced over time [1]. Both grief and bereavement are sub-
jective in their experience and duration. Bereaved
individuals who have not been through the process of
grief have an increased risk of mortality [2, 3], deterior-
ation of physical health [2], reduced cognitive function-
ing, increase in mental health challenges, and associated
illnesses [4]. These outcomes negatively impact the
socio-economic status of individuals while generating
high costs in already fragile economies of low-income
countries [5, 6]. Bereavement support is therefore an
essential and core component of palliative care defined
by the WHO [7, 8].
Bereavement is an under-researched field in African
countries, despite high mortality rates from communicable
diseases such as HIV, tuberculosis, and malaria; and non-
communicable diseases such as cancer, heart disease, sui-
cide, and sudden deaths [9, 10]. The WHO Global Palliative
Care Atlas, the Lancet Commission on Pain and Palliative
Care [11], and the World Health Resolution on Palliative
Care [12] have all identified a critical gap between the need
for, and provision of, palliative care (including bereavement
care). However, within this gap, there is further inequity.
Systematic reviews of the evidence in sub-Saharan Africa
have found that bereavement interventions are rarely de-
scribed within palliative care intervention studies [13, 14].
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Community-based interventions using already existing
structures, for example, local health cadres embedded in
the local health system, are more effective and widely ac-
cepted within low-resourced countries such as Zimbabwe,
whose socio-economic structures have vastly deteriorated
[15]. Previous studies have shown that local health cadres
trained to act as an extension of the central health centers
are effective in health delivery as they increase coverage
and access [16]. Caregivers from the communities that
local health services serve can offer in-depth knowledge of
local cultural preferences and practices for effective deliv-
ery and uptake of healthcare services [17–19].
This study will adopt the 9-cell bereavement interven-
tion developed in Zimbabwe. The 9-cell was designed to
assist individuals to reflect on their feelings in bereave-
ment and identify resources in families and communities
to manage bereavement. This process is intended to in-
crease the lay supporter’s understanding of the experience
of grief and to identify ways of increasing support to the
bereaved. The 9-cell bereavement tool explores the com-
munication that the bereaved currently receive, discussing
and linking their own grief and bereavement experiences
with the support they need at different stages [20]. This
person-centered approach is designed to provide context-
based, culturally appropriate, individually tailored support.
The tool was implemented in Tanzania and India, with
process data suggesting increases in awareness of the con-
cepts behind grief and the bereavement process, providing
rare opportunities to share experiences of both with fellow
community members. One year after the 2004 Tsunami,
an NGO funded a 10-week training and supervision pro-
gram to integrate the 9-cell bereavement tool into the
work of volunteer counselors in Tamil Nadu, India. Des-
pite these examples of use, there has been no rigorous
evaluation of the 9-cell [21].
There is an absence of effectiveness literature for be-
reavement interventions in sub-Saharan Africa [22–24].
However, the positive outcomes experienced in the few
documented interventions, including the 9-cell bereave-
ment tool as tested in other low-income countries simi-
lar to Zimbabwe, support the need for community-based
bereavement interventions to be scaled up. With this
knowledge and due to the potential vulnerability of
bereaved individuals, the scarcity of resources within
sub-Saharan Africa, it is essential to therefore establish
the feasibility of delivering and testing the tool using a
trial design, prior to investment and participant involve-
ment in a full clinical trial.
Methods
Aim and objectives
The aims of this study are to assess the feasibility of imple-
menting the 9-cell bereavement tool at the community level
and to determine the feasibility of evaluating the interven-
tion using a cluster randomized control trial design.
The objectives are (i) to determine the feasibility of
conducting a randomized cluster trial in terms of re-
cruitment and retention; (ii) to assess the feasibility of
implementing the 9-cell bereavement tool; (iii) to deter-
mine whether there would be contamination between
the clusters; (iv) to assess the acceptability and com-
pleteness of measures and data; (v) to identify trial par-
ticipants’ views and experience of the intervention and
its mechanisms of action; (vi) to estimate potential effect
size; and (vii) to determine whether a full trial is
warranted.
Feasibility questions and success criteria
We will seek to answer the following research questions:
(1) will we be able to recruit at least 75% of the sug-
gested sample size of interventionists and trial partici-
pants interventionists within 3 weeks? In order to meet
proposed trial timelines, we suggest trial recruitment cri-
teria of recruiting community leaders within 1 week; in-
terventionists within 1 week and the trial participants
within 1 week; giving a total recruitment period of
3 weeks. (2) Will we be able to retain at least 75% of
both the trial participants and the interventionists in the
total duration of the study? (3) Can we deliver the 9-cell
bereavement intervention as intended? (4) Will the pro-
cesses of a randomized cluster trial be possible? (5) Does
process data suggest that the anticipated effect is likely?
There is a paucity of guidance on setting progression
criteria for feasibility and pilot trials [25]. Therefore, we
draw on the MRC guidance that such criteria should be
judged in light of all study findings and used to refine
study design. Our recruitment and retention criterion of
75% was set in light of published feasibility trial criteria
and reflects the nature of our population (i.e., they are
community-dwelling bereaved individuals without any
known serious health conditions and so we anticipate
high retention).
Study design
A cluster feasibility randomized control trial with
nested qualitative focus groups will be used for this
study. Cluster randomization would be required in a
full trial as the intervention is delivered at the com-
munity level. Recruitment is estimated to take place
over an estimated 3-week period. It will include ap-
proaching and sensitization of community leaders;
identification and recruitment of interventionists;
qualitative data collection (FGD 1) with recruited in-
terventionists; and identification and recruitment of
trial participants.
The data collection timeline as illustrated in Fig. 1 will
be as follows:
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Week 0 Baseline data collection from trial participants
Randomization
Administering intervention to the intervention group
Week
14
Midline data collection from trial participants
Qualitative data collection (FDG 2) with the intervention
group
Week
27
Endline data collection from trial participants
Qualitative data collection (FDG 3) with the intervention
group
Qualitative data collection (FGD 4) from trial participants
Administering intervention to control group
Figure 1 presents the study flow chart. This is followed
by a narrative description of the data collection stages.
Timeline
Interventions are more effective when administered closer
(though not too soon) to the time of death of the loved
one [26, 27]. Six to 18months is a suitable period for
administering bereavement interventions inclusive of their
follow-up [26]. According to Jennifer Hunt, the developer
of the 9-cell bereavement tool, the 6-month mark usually
represents a time when social support often fades and the
reality of the loss sets in. Inclusion criteria (elaborated in
the “Recruitment” section below) of trial participants will
therefore be individuals in the community who have expe-
rienced the loss of a loved one in the past 6months from
the recruitment date (even where someone has been be-
reaved within a week of the study; by the time the study is
finished it will be over 9months, so they theoretically are
still eligible as 6 to 18months is a suitable period for ad-
ministering interventions inclusive of their follow-up as
indicated above).
Setting
This study will be conducted in Chitungwiza, a city
bordering the capital city of Zimbabwe. A local supporting
organization for this study, Island Hospice and Healthcare
(IHH), has been involved in community work in
Chitungwiza for the past 15 years engaging community
groups, community leaders, non-governmental organiza-
tions (NGOs), churches, and government ministries.
Two broadly similar communities within Chitungwiza
have been selected; one will act as the intervention
group (IG) and the other as the control group (CG).
Chitungwiza is densely populated with a large surface
area, which greatly reduces potential contamination
between the two selected intervention and control areas.
Figure 2 provides the map of Chitungwiza; one
community cluster is in the north-west section and the
second is in the south-east, therefore reducing the likeli-
hood of contamination. They have similar socio-demo-
graphic characteristics and value systems, with the
economy being largely supported by informal trade and
falling under the same traditional territory and health
administration. The two communities selected within
Chitungwiza are about 8 km apart. Through discussion
with local stakeholders, 8 km is anticipated to be ad-
equate distance and corresponding density to reduce
possible contamination between the two clusters. How-
ever, as an added precaution, the control group will be
asked at midline and at endline to establish whether they
have visited the community where the intervention took
place and if they had a discussion with any community
member who received the intervention.
A local community hall or other forms of available and
convenient gathering space will be identified in the
respective communities as central data collection venues.
The community leaders assisting in the recruitment
processes will assist in identifying central venues
convenient to participants recruited for the interventions
and the study. Recruitment processes are detailed in the
following section.
Sample size
Past research has recommended sample sizes of 24 and
50 [28–31]. For this feasibility study, sample sizes for
Fig. 1 Study flow chart
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community leaders have been set at 25 in total, and for
interventionists, at 25 per cluster; with the trial
participants set at 75. The target is 50; however, a reach
of 75 has been set, to allow for any challenges in
recruitment and for possible attrition from the study.
Recruitment
The recruitment process follows three stages.
Stage 1: Recruitment of community leaders
The recruitment process will begin with study engagement
using existing relationships that Island Hospice and
Healthcare (IHH) has with community leaders (CL) from
the selected two communities in Chitungwiza. The
rationale, goals, and intended procedures of the study will
be explained, community leader permission sought to
undertake the research, and support from the community
leaders (CL) requested to deliver the study. This is an
essential step in conducting community-based research in
this context.
Stage 2: Recruitment of potential interventionists by
community leaders
The community leaders (CL) will be tasked to invite 25
people (i.e., potential interventionists) from their respective
communities to attend a meeting. Inclusion criteria for
potential interventionists will include individuals from the
two selected communities of Chitungwiza which the CL
serve; recruited by the community leaders; be aged at least
18 years of age; be able to either verbally consent or be able
to consent in writing; be able to read and write; and
expected to be able to deliver the lay community peer
intervention. At the meeting, the potential interventionists
will be provided with information about the study and
asked to give informed consent, to participate in the study.
Interventionists will complete a short questionnaire that
will assess their socio-demographic background and be-
reavement history. The questionnaire is self-administered.
The researchers will provide instruction to the interven-
tionists and be available to assist with clarification of any
questions where required. The third activity is a focus
group discussion (FGD#1 as illustrated in Fig. 1) with the
interventionists, to assess the feasibility of them identifying
potential trial participants and inviting them to meet with
the researchers, to learn more about the study.
Stage 3: Recruitment of potential trial participants
The potential interventionists from each community will be
tasked to identify 2 to 3 people according to the following
criteria. Potential participants must be (a) at least 18 years
old, (b) resident within their neighborhoods, (c) someone
with whom they interact with on a daily basis, (d) whom
they know to have been bereaved in the past 6months, (e)
would have the ability to either verbally consent or be able
to consent in writing, (f) be able to read and write, and (g)
be expected to attend and participate in the study. Potential
participants who meet all of these criteria will be invited to
a meeting where information regarding the study will be
shared. Researchers will obtain consent from potential trial
participants.
Following written informed consent, potential trial
participants will be invited to participate in the study.
Fig. 2 Map of Chitungwiza
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Participating in the study includes completing
questionnaires at baseline (T0, i.e., week 0), midline (T1,
i.e., 3 months post-baseline or week 14), and endline
(T2, i.e., 3 months post-midline or at week 27), with a
subsample of the intervention cluster participants in-
vited to qualitative focus group interviews to better
understand participants’ views on study participation
and intervention mechanisms of action. Focus group
participants will be aged at least 18 years of age; be able
to either verbally consent or be able to consent in writ-
ing; and be able to verbally share their experiences and
thoughts regarding the study.
Retention of interventionists and trial participants
Registration forms will include full names and contact
details of both interventionists and trial participants.
Contact details will be used to notify both
interventionists and trial participants, of the planned
data collection dates respectively. For example, mobile
phone messages will be sent to all both the
interventionists and the trial participants, requesting
and reminding them of the dates for baseline, midline,
and endline data collection.
Stage 4: Baseline data collection from trial participants
Once recruited into the study, the trial participants (n =
25 per community) will complete self-report question-
naires, both demographic and validated outcome mea-
sures. Data collection will be on different days for each
community, but within a space of a week. Questionnaires
will be self-administered, with assistance from researchers
where needed. Trained surveyors will go through some
sample questions with the respondents in order to
familiarize them with the questionnaire format. The sur-
veyors will be present to assist respondents who may
require further assistance beyond initial instructions.
Completing the questionnaires is estimated to take less
than an hour.
The questionnaires used were selected as they are in
line with the intended intervention outcomes, have been
successfully tested to be culturally specific adaptation,
have been used by other researchers in Africa and or
other low- and middle-income countries, and their ease
of understanding and therefore administration.
These are the Shona Symptom Questionnaire (SSQ,
measure mental health), the Modified Social Support
Survey (MSSS, measures social support), and the Texas
Revised Inventory of Grief (TRIG, measures levels of grief).
The SSQ was developed in Zimbabwe. It incorporates 14
questions, 7 of which are etic (global concept) and 7 are
emic (culturally specific). The MSSS has 20 questions based
on 4 subscales of emotional/informational, tangible,
affectionate, and positive social interactions [32]. The TRIG
is a 13-item, self-report measure of current feelings related
to the loss [33]. As an illustration of their successful adapt-
ability in different and varied cultural settings and lan-
guages, the MSSS and the TRIG have both been
successfully used in both low- and high-income countries
including Brazil—Portuguese language [34]; the USA [35];
in French Canada [36]; in New Mexico [37]; Norway [38];
and Spain [39].
Stage 5: Randomization
Random allocation will be conducted by a statistician
independent of the study, who will use an electronic
system to randomly allocate the two clusters to
intervention (IG) and control group (CG). Both the
researchers (except the principal investigator) and the
data analyst will not be aware of which cluster will be
the intervention group and which one will be the
control group. This blinding reduces the influence that
researchers may have when collecting the quantitative
datasets from the community clusters [40] and any
influence that the data analyst will have when analyzing
the same data sets. The 25 potential interventionists in
the allocated intervention cluster will receive the
training and the 9-cell bereavement tool, as explained in
Stage 6 below. The control group will be waitlisted to re-
ceive the intervention at the end of the study (following
final endline data collection point).
Stage 6: Intervention
The 25 lay community members in the cluster randomized
to be the intervention group (IG) will take part in the
intervention of the 9-cell bereavement tool. The ex-be-
reavement service coordinator and trainer, responsible for
the development of the 9-cell bereavement tool, will ad-
minister the 9-cell bereavement tool with assistance and
translation from one Island Hospice Healthcare (IHH) so-
cial worker. Before the intervention, the trainer will provide
intensive pre-intervention preparation with the IHH social
worker in order to transfer skills to IHH as a secondary
benefit of the study. IHH will support the administration
of the 9-cell tool in the identified communities.
The 9-cell bereavement tool is administered in a 7-h
(1 day) session. Community lay caregivers are an appro-
priate target as social support can improve grief and
bereavement outcomes [41, 42].
It assesses personal feelings in relation to
bereavement, identifies judgmental attitudes,
inappropriate religious tenets, lack of understanding,
effects of family, and community support. The 9-cell
bereavement tool places the uniquely personal journey
of grief firmly within the social setting in which grief is
processed; how to ensure a better fit for the grieving in-
dividual within their society; is particularly useful in
multicultural settings; and was developed from experi-
ence from local bereavement beliefs and practices.
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The overall process of implementing the 9-cell
bereavement tool:
 Builds on people’s existing knowledge and
experience
 Models an open-minded and non-judgmental
approach
 Recognizes great diversity in grief experiences in
individuals, genders, families, cultures, and faiths
 Encourages intervention participants to listen to
others while helping them to break down barriers of
previously held beliefs about grief
Transport fees, incentives, and refreshments will be
provided during the intervention as in the data
collection phase of the study.
Stage 7: Midline data collection
At T1 (at week 14 of 3 months following baseline), all
participants from both clusters will be invited to
complete the questionnaires listed above. Data collection
for the intervention group and the control group will be
held on different days. Through discussion with local
stakeholders, 8 km was anticipated to be adequate
distance and corresponding density to reduce possible
contamination between the two clusters. However, as an
added precaution, the control group will be asked at
midline and at endline to establish whether they have
visited the community where the intervention took place
and if they had a discussion with any community
member who received the intervention.
Immediately after T1 midline data collection with trial
participants, interventionists will be invited back to
participate in a second focus group discussion (FGD#2 as
identified in the study flow chart in Fig. 1). The
semi-structured discussion guides with open-ended ques-
tions allow for in-depth explanations and descriptions of
subjective experiences [43]. Open-ended questions en-
courage focus group participants to share their lived expe-
riences without the constraints of structured tools [43].
The purpose of this second focus group discussion would
be to appraise the intervention training received 3months
prior, and their ability to deliver the intervention in line
with the information provided. Questions will be centered
around their experience of their own bereavement process
following the intervention, how they delivered the inter-
vention, when they started to feel changes within them-
selves around the intervention concepts, the language
they started using with others going through the same be-
reavement process, any changes in the way they interacted
with others around bereavement, and the support they feel
they would need currently and in the future, related to the
intervention elements learned. FGD will take up to 45min
(see procedures below). The group discussions will be led
by the principal investigator (BM) supported by a research
assistant who will take notes. The discussions will be held
in the respective communities, with refreshments and in-
centives provided as appreciative tokens for the respon-
dents’ participation. Focus group discussions will be
recorded with the participants’ permission (included in
the informed consent form), and deleted once transcribed
verbatim.
Stage 8: Endline data collection (T2)
At T2 (endline data collection; week 27 or 3months
post-midline), all trial participants will complete the ques-
tionnaires following procedures for the quantitative data
collection described above. An additional data collection
process will occur with the intervention group (IG). As they
complete the final endline questionnaire, 10 to 15 partici-
pants will be purposively recruited into a focus group
(FGD#4 as indicated in Fig. 1—the study flow chart). Pur-
posive sampling will guide in recruiting at least an equal
number per gender and age. In the group discussion, the
principal investigator will share information about the
intervention to the intervention group trial participants.
Following the explanation, the trial participants, will join in
a discussion centered on why they agreed to be in the
study, what it was like for them, how often they saw the
interventionist who recruited them into the study, what
they discussed regarding bereavement, what they learnt to
do or feel differently following the discussions, who initi-
ated the discussions they had with the interventionists, any
negative and or positive thoughts or actions that followed,
discussions with others outside of the intervention, how the
study helped, and if they felt they needed extra support they
may require following the end of the study.
Once baseline, midline, and endline data collection,
including the focus group discussions (FGD 1, 2, and 4, as
indicated in the study flow chart in Fig. 1), a separate focus
group discussion (FGD # 3) will be held with
interventionists to assess their experience in interacting
with the bereaved within their communities. This topic
guide will ask questions around how they maintained the
conversations with regard to bereavement with those in
their communities, was it sustainable, were there any
changes they noticed from the community in their renewed
communication, do people actively seek them out, are they
sort after, what do people want to discuss when they see
them, are there self-described gains and if so what are they,
will they use any of the lessons learned going forward, what
will they use, what do they need to sustain this, and does
anyone outside the trial ask for support from them?
Data management
Confidentiality
All completed consent forms will be kept in a locked
room and cupboard at IHH, the local supporting
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organization. Only recognized research team members
will have access. All analysis will be performed and
saved on a password-protected laptop. No names will be
included on the data collected; code/questionnaire num-
bers will have code numbers allocated to each respond-
ent/participant’s responses. Questionnaires will be stored
separately from the information and consent forms.
Only the questionnaires will have the study ID numbers,
not the information and consent forms. This further re-
duces any cross analysis.
Compensation
All participants will be reimbursed for public transport to
the study sites and will be provided with light
refreshments at the venue. Participants will receive a small
token of appreciation, valued at approximately USD3, to
compensate them for the time taken to participate in the
study. For their convenience, data collection will take
place within the respective communities where the
participants reside. Transport fare of an equivalent of
USD2 will be provided to each participant.
Risks
While it is believed that no harm can occur during this
research, risks may include challenges in processing
grief, high emotional burden, or distress. The 9-cell be-
reavement tool developer (JH) and a trained social
worker from Island Hospice and Healthcare will be
available during the sessions to assist where needed as
they will be administering the intervention and are
trained in counseling and working with the bereaved
and highly distressed individuals. In addition, and as this
project is supported by Island Hospice and Healthcare,
participants can be referred for further counseling and
assistance throughout the intervention period and fol-
lowing the evaluation.
Data monitoring
Data monitoring (recruitment, retention, adverse events)
will be reported to the Steering Committee meetings
(chaired by the Chief Investigator, Richard Harding) by
the local principal investigator (Barbara Mutedzi) for
review.
Data analysis
Quantitative data will be entered into a study-specific
excel spreadsheet prior to import to SPSS for analysis.
In terms of recruitment, we will calculate the
proportion of the target sample achieved for community
lay interventionists and trial participants.
With respect to retention, we will calculate the
proportion of potential trainees recruited who attended
the full day training, and the proportion who remained
active in bereavement support until trial end. We will
report the proportion of trial participants who
participate in T0 (baseline of week 0), T1 (midline at
week 14 or 3 months post-baseline), and T2 (at week 27
or 3 months post-midline) data collection.
In terms of the outcome data, we will measure data
completeness at each timepoint. We will plot data to
check for floor and ceiling effects (to help us inform
primary outcome selection), report data completeness,
and plot means/standard deviations or medians and IQR
(depending on data normality/symmetry of distribution)
for each timepoint. We will appraise the selected outcome
measures in terms of the qualitative explanation of
perceived intervention benefits (and potential unintended
consequences).
We will estimate potential treatment effect size using
longitudinal methods for non-parametric data (no in-
terim analysis), using an appropriate method (e.g.,
ANCOVA adjusting for baseline scores, with 95% confi-
dence intervals). With regard to contamination, if we
find that 8 km was a sufficient distance to minimize con-
tamination, then we will (in full trial development) de-
termine clusters that meet this criterion, which appears
possible within Zimbabwe.
Verbatim transcripts of the individual and focus group
interview data will be imported into NVIVO for analysis
using the framework approach [44]. The trial participant
and interventionist datasets will be analyzed separately.
The thematic analysis will populate the framework by
case analysis to generate themes, with the matrix
permitting between-case comparison. Data will be inte-
grated by appraising the quantitative outcomes in light
of the qualitative description, with parity between the
data types.
We will measure success in terms of our a priori
criteria stated above, and if necessary refine methods by
integrating the qualitative and quantitative data. If
success criteria have not been met, refinements will aim
to improve the design.
Discussion
This study will assess the feasibility of implementing the
9-cell bereavement tool at a community level and to de-
termine the feasibility of evaluating the intervention
using a cluster randomized control trial design. This will
enable us to determine optimal successful design for a
full trial in an area that is currently neglected in the lit-
erature but has an enormous potential public health
benefit. This protocol will enable us to provide a trans-
parent analysis of the feasibility trial and reduce report-
ing bias [45]. We will appraise the results against the
stated success criteria.
To reduce reporting bias, findings will be submitted
for publication in peer-reviewed journals and be
shared through the ethics review committees for
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wider distribution. Study results will guide a national
bereavement strategy, promoting intervention dissem-
ination across communities in Zimbabwe. Positive re-
sults from this study would support intervention
rollout to many other African countries and training
related to the feasibility study, and its methods will
be shared regionally with other researchers in the
same program.
Ethics
Ethical approval was obtained from King’s College
London (17/18-5415) and from the Medical Research
Council of Zimbabwe (MRCZ) reference number
MRCZ/A/2230.
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